|9.15 0.28 (3.16%)||12-01 16:00|
|Targets||6-month :||10.9||1-year :||12.74|
|Resists||First :||9.34||Second :||10.9|
|Supports||First :||7.59||Second :||6.51|
|MAs||MA(5) :||8.81||MA(20) :||7.95|
|MA(100) :||7.27||MA(250) :||8.07|
|MACD||MACD :||0.4||Signal :||0.3|
|%K %D||K(14,3) :||88.2||D(3) :||90.6|
|52-week||High :||10.8||Low :||5.76|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZYME ] has closed below upper band by 7.1%. Bollinger Bands are 102.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||9.18 - 9.21||9.21 - 9.24|
|Low:||8.64 - 8.67||8.67 - 8.71|
|Close:||9.09 - 9.14||9.14 - 9.2|
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||70 (M)|
|Shares Float||42 (M)|
|Held by Insiders||4.8 (%)|
|Held by Institutions||96.4 (%)|
|Shares Short||2,420 (K)|
|Shares Short P.Month||4,680 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||6.25|
|Profit Margin||44.4 %|
|Operating Margin||-201.3 %|
|Return on Assets (ttm)||29.7 %|
|Return on Equity (ttm)||67.9 %|
|Qtrly Rev. Growth||527.4 %|
|Gross Profit (p.s.)||2.91|
|Sales Per Share||6.59|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||195 (M)|
|Levered Free Cash Flow||111 (M)|
|Price to Book value||1.46|
|Price to Sales||1.38|
|Price to Cash Flow||3.28|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|